Jai Lara Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 25-06-2024
- Paid Up Capital ₹ 1.31 Cr
as on 25-06-2024
- Company Age 14 Year, 19 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 16.31 Cr
as on 25-06-2024
- Satisfied Charges ₹ 7.40 Cr
as on 25-06-2024
- Revenue -22.36%
(FY 2023)
- Profit -61.23%
(FY 2023)
- Ebitda -11.81%
(FY 2023)
- Net Worth 7.17%
(FY 2023)
- Total Assets 52.85%
(FY 2023)
About Jai Lara Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 1.31 Cr.
The company currently has active open charges totaling ₹16.31 Cr. The company has closed loans amounting to ₹7.40 Cr, as per Ministry of Corporate Affairs (MCA) records.
Manindhar Reddi and Sanndhya Ranni serve as directors at the Company.
- CIN/LLPIN
U24100TG2010PTC071922
- Company No.
071922
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Jai Lara Drugs Private Limited offer?
Jai Lara Drugs Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Psychotherapeutic Agents, Antidepressant & Anti Anxiety Medicines, Pregabalin Capsules, Pharma Ingredients & Raw Materials, Blood System and Cardiovascular API, Esomeprazole Drugs, Esomeprazole Capsule.
Who are the key members and board of directors at Jai Lara Drugs?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manindhar Reddi  | Director | 29-Dec-2010 | Current |
| Sanndhya Ranni | Director | 29-Dec-2010 | Current |
Financial Performance of Jai Lara Drugs.
Jai Lara Drugs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.36% decrease. The company also saw a substantial fall in profitability, with a 61.23% decrease in profit. The company's net worth moved up by a moderate rise of 7.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jai Lara Drugs?
Unlock access to Jai Lara Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Srilara Labs Private LimitedActive 6 years 3 monthsManindhar Reddi and Sanndhya Ranni are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 12 Oct 2022 | ₹3.51 M | Open |
Others Creation Date: 15 Jun 2022 | ₹4.19 Cr | Open |
Others Creation Date: 11 Apr 2022 | ₹8.00 M | Open |
How Many Employees Work at Jai Lara Drugs?
Jai Lara Drugs has a workforce of 93 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jai Lara Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jai Lara Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
